Connection

GREG CUNY to Activin Receptors, Type I

This is a "connection" page, showing publications GREG CUNY has written about Activin Receptors, Type I.
Connection Strength

0.405
  1. Discovery of 3-(4-sulfamoylnaphthyl)pyrazolo[1,5-a]pyrimidines as potent and selective ALK2 inhibitors. Bioorg Med Chem Lett. 2018 11 01; 28(20):3356-3362.
    View in: PubMed
    Score: 0.154
  2. Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants. J Med Chem. 2014 Oct 09; 57(19):7900-15.
    View in: PubMed
    Score: 0.117
  3. Development of an ALK2-biased BMP type I receptor kinase inhibitor. ACS Chem Biol. 2013; 8(6):1291-302.
    View in: PubMed
    Score: 0.107
  4. A new class of small molecule inhibitor of BMP signaling. PLoS One. 2013; 8(4):e62721.
    View in: PubMed
    Score: 0.027
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.